Keratolytic Ophthalmic Composition for MGD With Reduced Irritation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meibomian gland dysfunction (MGD) causes dry eyes and blepharitis due to insufficient meibum production, with existing treatments like selenium disulfide causing adverse effects at high concentrations.
Innovation Solution
An ophthalmic preparation containing keratolytic agents, such as selenium disulfide, is administered to improve objective measures and symptoms of ocular disorders by evaluating and adjusting treatment based on objective scores to minimize adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of selenium disulfide are used to treat meibomian gland dysfunction, then therapeutic benefit is improved, but adverse effects such as pain, local irritation, and inflammation increase
Solution Approach 1:
The patent applies parameter changes by optimizing the concentration of selenium disulfide in the ophthalmic preparation. Instead of using high concentrations that cause adverse effects, the formulation uses controlled, lower concentrations that provide therapeutic benefit while minimizing harm. This resolves the contradiction by finding the optimal parameter value that balances efficacy and safety.
2Measurement precision
If keratolytic agents are applied to improve meibomian gland function, then objective measures improve rapidly, but symptom improvement is delayed
Solution Approach 1:
The patent applies preliminary action by using keratolytic agents that first address the underlying objective measures (meibomian gland morphology and function) before symptom relief fully manifests. The treatment targets the root cause—keratinization and gland obstruction—so that improvements in objective measures precede and eventually lead to symptom improvement, which may be delayed by several months.
3Reliability
If extended treatment with keratolytic agents is administered, then symptom improvement increases, but treatment duration and monitoring complexity increase
Solution Approach 1:
The patent applies feedback by implementing a monitoring system that evaluates objective measures at multiple time points during extended treatment. This allows clinicians to assess treatment response and adjust the duration and dosage of keratolytic agents accordingly. The feedback mechanism ensures that treatment continues long enough to achieve symptom improvement while avoiding unnecessary extended use, thus balancing reliability with treatment duration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significant improvements in meibomian gland function and symptom reduction are observed over time, with reduced adverse events, indicating a balanced treatment approach.
Implementation Method 1
ophthalmic preparations of selenium disulfide may be applied to the eyelid, eyelid margin, ocular surface, or surrounding tissues... providing a keratolytic agent (e.g., selenium disulfide) to or around the eye of the individual
Data Source
AI summary
Provided herein are methods for improving signs and symptoms of ocular indications and treating ocular disorders using a keratolytic agent.